{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:47:11Z","timestamp":1791002831322,"version":"4.1.0"},"reference-count":140,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combined oral contraceptives (COCs) induce several changes in the levels of coagulation factors. The levels of procoagulant factors are often increased, while levels of anticoagulant factors are decreased. Fibrinolysis is also affected, even if the effect seems to be more counterbalanced by opposite regulation of profibrinolytic and antifibrinolytic factors. These effects on hemostasis are more pronounced with third- or fourth-generation COC compared with second-generation COC. Venous thromboembolism (VTE) risk increases when multiple risk factors, including genetic and environmental, are present simultaneously. COC use causes changes in coagulation that modify the prothrombotic state induced by preexisting hemostatic alterations in a supra-additive manner. Therefore, testing appears to be of importance not only before implementing COC but also to monitor any potential thrombogenicity induced by COC therapy. Inherited genetic factors, such as factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C or protein S deficiencies, non-O blood group, as well as CYP2C9*2 and the rs4379368 mutations, have all been identified as genetic predictive risk factors of VTE in women. Nevertheless, the screening of these genetic biomarkers is not capable of assessing the phenotypic expression of the risk. This review will focus on the different options for screening the thrombogenic status in this population. Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquired thrombophilia.<\/jats:p>","DOI":"10.1055\/s-0040-1714140","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:09:41Z","timestamp":1603235381000},"page":"872-886","source":"Crossref","is-referenced-by-count":40,"title":["Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk"],"prefix":"10.1055","volume":"46","author":[{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[{"name":"QUALIblood s.a., Namur, Belgium"},{"name":"Department of Pharmacy, Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Morimont","sequence":"additional","affiliation":[{"name":"QUALIblood s.a., Namur, Belgium"},{"name":"Department of Pharmacy, Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bouvy","sequence":"additional","affiliation":[{"name":"QUALIblood s.a., Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the global disease burden","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref2","author":"R LK Virchow","year":"1910"},{"issue":"05","key":"ref3","first-page":"885","article-title":"Classic thrombophilic gene variants","volume":"114","author":"P M Mannucci","year":"2015","journal-title":"Thromb Haemost"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/5584_2016_120","article-title":"Genetic risk factors in venous thromboembolism","volume":"906","author":"C Hotoleanu","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajhg.2015.01.019","article-title":"Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism","volume":"96","author":"M Germain","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1055\/s-0037-1615956","article-title":"Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis","volume":"85","author":"M C de Visser","year":"2001","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/s-0038-1642511","article-title":"Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS)","volume":"71","author":"T Koster","year":"1994","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"J C Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"A van Hylckama Vlieg","year":"2000","journal-title":"Blood"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"L Gallinaro","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"P V Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.ATV.20.5.1382","article-title":"Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V Leiden, and relation with factor VIII antigen levels","volume":"20","author":"P W Kamphuisen","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"I M Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.15608","article-title":"Venous thromboembolism and women's health","volume":"183","author":"V Speed","year":"2018","journal-title":"Br J Haematol"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"M D Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"issue":"20","key":"ref16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"J P Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","article-title":"History of oral contraceptive drugs and their use worldwide","volume":"27","author":"S Christin-Maitre","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/humrep\/det023","article-title":"Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study","volume":"28","author":"E M Mikkelsen","year":"2013","journal-title":"Hum Reprod"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","journal-title":"Lancet"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1055\/s-0038-1641152","article-title":"Type of combined contraceptives, factor V Leiden mutation and risk of venous thromboembolism","volume":"118","author":"J Hugon-Rodin","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"J P Vandenbroucke","year":"1994","journal-title":"Lancet"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1160\/TH15-06-0478","article-title":"Uncertain thrombophilia markers","volume":"115","author":"M Franchini","year":"2016","journal-title":"Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"d4656","DOI":"10.1136\/bmj.d4656","article-title":"Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study","volume":"343","author":"J Hippisley-Cox","year":"2011","journal-title":"BMJ"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"e005809","DOI":"10.1136\/bmjopen-2014-005809","article-title":"The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study","volume":"4","author":"J Hippisley-Cox","year":"2014","journal-title":"BMJ Open"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40258-017-0318-x","article-title":"Economic evaluations of thrombophilia screening prior to prescribing combined oral contraceptives: a systematic and critical review","volume":"15","author":"E Vernon","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3390\/jpm9010004","article-title":"Re-examining genetic screening and oral contraceptives: a patient-centered review","volume":"9","author":"B Hiedemann","year":"2019","journal-title":"J Pers Med"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1160\/TH08-03-0149","article-title":"Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis","volume":"100","author":"K J Smith","year":"2008","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"e0182041","DOI":"10.1371\/journal.pone.0182041","article-title":"Risk prediction of developing venous thrombosis in combined oral contraceptive users","volume":"12","author":"A McDaid","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"e031325","DOI":"10.1136\/bmjopen-2019-031325","article-title":"Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland","volume":"9","author":"C S Sutherland","year":"2019","journal-title":"BMJ Open"},{"issue":"18","key":"ref39","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"S R Kahn","year":"2014","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9378(87)80129-1","article-title":"Coagulation effects of oral contraception","volume":"157","author":"J Bonnar","year":"1987","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1471-0528.1979.tb10795.x","article-title":"Changes in coagulation factors in postmenopausal women on ethinyl oestradiol","volume":"86","author":"D J Hunter","year":"1979","journal-title":"Br J Obstet Gynaecol"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","article-title":"Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives","volume":"60","author":"G M Harris","year":"1999","journal-title":"Am J Hematol"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0049-3848(99)00233-9","article-title":"The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study","volume":"98","author":"E Hoibraaten","year":"2000","journal-title":"Thromb Res"},{"issue":"09","key":"ref44","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1538-7836.2004.00894.x","article-title":"Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives","volume":"2","author":"M Alhenc-Gelas","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/17512433.2017.1356718","article-title":"Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis","volume":"10","author":"M Farris","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"07","key":"ref46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2016.1190832","article-title":"Metabolic impact of combined hormonal contraceptives containing estradiol","volume":"12","author":"G Grandi","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/1354750X.2016.1204010","article-title":"Sex hormone-binding globulin and thrombin generation in women using hormonal contraception","volume":"22","author":"J Hugon-Rodin","year":"2017","journal-title":"Biomarkers"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0037-1612973","article-title":"Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation","volume":"87","author":"J M Kemmeren","year":"2002","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"C Klipping","year":"2011","journal-title":"Drugs R D"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol","volume":"73","author":"C Kluft","year":"2006","journal-title":"Contraception"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1160\/TH04-11-0762","article-title":"Effect of oral contraceptives on the anticoagulant activity of protein S in plasma","volume":"93","author":"R R Koenen","year":"2005","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0010-7824(95)00098-U","article-title":"Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins","volume":"51","author":"I Wiegratz","year":"1995","journal-title":"Contraception"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol","volume":"95","author":"C Kluft","year":"2017","journal-title":"Contraception"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"J Rosing","year":"1997","journal-title":"Br J Haematol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ob.1998.v179.a92633","article-title":"Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review","volume":"179","author":"U H Winkler","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0010-7824(98)00045-6","article-title":"A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel","volume":"57","author":"U H Winkler","year":"1998","journal-title":"Contraception"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1538-7836.2003.t01-2-00177.x","article-title":"Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system","volume":"1","author":"P G Lindqvist","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","year":"2003","journal-title":"Contraception"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens","volume":"20","author":"H A van Vliet","year":"2005","journal-title":"Hum Reprod"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7836.2008.02863.x","article-title":"Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor","volume":"6","author":"H A van Vliet","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.thromres.2013.12.041","article-title":"Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives","volume":"133","author":"M Raps","year":"2014","journal-title":"Thromb Res"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"e105007","DOI":"10.1371\/journal.pone.0105007","article-title":"Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study","volume":"9","author":"H R\u00fchl","year":"2014","journal-title":"PLoS One"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/13625187.2015.1050091","article-title":"Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review","volume":"20","author":"I Lete","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.thromres.2014.09.008","article-title":"Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives","volume":"134","author":"S N Tchaikovski","year":"2014","journal-title":"Thromb Res"},{"issue":"08","key":"ref65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ajh.24064","article-title":"Hypercoagulability in adolescent girls on oral contraceptives-global coagulation profile and estrogen receptor polymorphisms","volume":"90","author":"A Zia","year":"2015","journal-title":"Am J Hematol"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.contraception.2015.09.015","article-title":"Clotting factor changes during the first cycle of oral contraceptive use","volume":"93","author":"C L Westhoff","year":"2016","journal-title":"Contraception"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"e0206376","DOI":"10.1371\/journal.pone.0206376","article-title":"The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index","volume":"13","author":"A BO Mohamed","year":"2018","journal-title":"PLoS One"},{"issue":"09","key":"ref68","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/clinchem\/31.9.1533","article-title":"Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma","volume":"31","author":"A Adam","year":"1985","journal-title":"Clin Chem"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"U M \u00c5gren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09513590500430328","article-title":"Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters","volume":"22","author":"J M Aldrighi","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0002-9378(99)70366-2","article-title":"The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors","volume":"181","author":"D F Archer","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0010-7824(93)90141-S","article-title":"Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel","volume":"48","author":"A Basdevant","year":"1993","journal-title":"Contraception"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0010-7824(94)90051-5","article-title":"Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive","volume":"50","author":"A C Cachrimanidou","year":"1994","journal-title":"Contraception"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0010-7824(01)00236-0","article-title":"A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism","volume":"64","author":"J Endrikat","year":"2001","journal-title":"Contraception"},{"issue":"06","key":"ref75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0010-7824(01)00213-X","article-title":"A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control","volume":"63","author":"F Fruzzetti","year":"2001","journal-title":"Contraception"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17\u03b2-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"P Gaussem","year":"2011","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0038-1653788","article-title":"Sensitivity to activated protein C; influence of oral contraceptives and sex","volume":"73","author":"C M Henkens","year":"1995","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0049-3848(91)90343-U","article-title":"Contact activation factors in plasma from women using oral contraceptives--increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein","volume":"64","author":"N-O Hoem","year":"1991","journal-title":"Thromb Res"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.contraception.2005.01.006","article-title":"A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel","volume":"72","author":"J Jespersen","year":"2005","journal-title":"Contraception"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0038-1657871","article-title":"Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator","volume":"54","author":"J Jespersen","year":"1985","journal-title":"Thromb Haemost"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0002-9378(90)90590-4","article-title":"Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid","volume":"163","author":"J Jespersen","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"08","key":"ref82","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/11590220-000000000-00000","article-title":"Metabolic and haemostatic effects of estradiol valerate\/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study","volume":"31","author":"W Junge","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"C Klipping","year":"2005","journal-title":"Contraception"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"T W Meade","year":"1977","journal-title":"Lancet"},{"issue":"01","key":"ref85","first-page":"9","article-title":"Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives","volume":"84","author":"J C Meijers","year":"2000","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0010-7824(91)90123-W","article-title":"A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors","volume":"43","author":"G B Melis","year":"1991","journal-title":"Contraception"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00001721-199701000-00006","article-title":"Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals","volume":"8","author":"G A Nicolaes","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1471-0528.1996.tb09716.x","article-title":"The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives","volume":"103","author":"L A Norris","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"issue":"06","key":"ref89","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0010-7824(99)00044-X","article-title":"An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol","volume":"59","year":"1999","journal-title":"Contraception"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1076029612463426","article-title":"Comparison of the impact of four generations of progestins on hemostatic variables","volume":"20","author":"S Oslakovic","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"334","DOI":"10.12891\/ceog3223.2016","article-title":"Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study","volume":"43","author":"K Peters","year":"2016","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01709663","article-title":"Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells","volume":"67","author":"P Quehenberger","year":"1993","journal-title":"Ann Hematol"},{"issue":"04","key":"ref93","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1160\/TH12-10-0771","article-title":"The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI","volume":"109","author":"M Raps","year":"2013","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jth.12172","article-title":"Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial","volume":"11","author":"M Raps","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref95","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1471-0528.1991.tb15364.x","article-title":"A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Task Force on Oral Contraceptives--WHO Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland","volume":"98","year":"1991","journal-title":"Br J Obstet Gynaecol"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0010-7824(95)00271-5","article-title":"A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol","volume":"53","author":"U Winkler","year":"1996","journal-title":"Contraception"},{"issue":"05","key":"ref97","first-page":"265","article-title":"Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women","volume":"46","author":"A C Ferreira","year":"2001","journal-title":"Int J Fertil Womens Med"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives","volume":"10","author":"M Raps","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"S N Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref100","first-page":"315","article-title":"Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism","volume":"10","author":"C Bastianelli","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"05","key":"ref101","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.thromres.2012.02.042","article-title":"Progestin-only contraception and venous thromboembolism","volume":"129","author":"M A Blanco-Molina","year":"2012","journal-title":"Thromb Res"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2004.07.009","article-title":"Progestogen-only contraception in women at high risk of venous thromboembolism","volume":"70","author":"J Conard","year":"2004","journal-title":"Contraception"},{"issue":"03","key":"ref103","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jth.12484","article-title":"Endogenous sex hormones and risk of venous thromboembolism in women and men","volume":"12","author":"H N Holmegard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref104","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ije\/20.4.913","article-title":"A multicentre study of coagulation and haemostatic variables during oral contraception: variations with geographical location and ethnicity. Task Force on Oral Contraceptives--WHO Special Programme of Research, Development and Research Training in Human Reproduction","volume":"20","author":"I Leck","year":"1991","journal-title":"Int J Epidemiol"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0038-1646528","article-title":"A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters","volume":"61","author":"U B Lindberg","year":"1989","journal-title":"Thromb Haemost"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0140-6736(67)91679-0","article-title":"Thrombosis and oestrogens","volume":"2","author":"M F Oliver","year":"1967","journal-title":"Lancet"},{"issue":"03","key":"ref107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/EJE-09-0284","article-title":"Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Troms\u00f8 Study","volume":"161","author":"T Vikan","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"03","key":"ref108","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","author":"M de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/OAJC.S179673","article-title":"Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?","volume":"9","author":"F Fruzzetti","year":"2018","journal-title":"Open Access J Contracept"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13625187.2018.1442911","article-title":"Book of Abstracts: The 15th Congress of the European Society of Contraception and Reproductive Health","volume":"23","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"08","key":"ref112","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2010.03953.x","article-title":"The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy","volume":"8","author":"C N Bagot","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref113","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"C A Mashchak","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"04","key":"ref114","first-page":"9S","article-title":"Pharmacokinetics of estrogen","volume":"75","author":"P G Stumpf","year":"1990","journal-title":"Obstet Gynecol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jsbmb.2008.12.013","article-title":"Clinical applications for estetrol","volume":"114","author":"M Visser","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(02)07813-3","article-title":"Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state","volume":"359","author":"R A Ari\u00ebns","year":"2002","journal-title":"Lancet"},{"issue":"03","key":"ref117","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/ATVBAHA.108.182188","article-title":"Biomarkers and venous thromboembolism","volume":"29","author":"I Pabinger","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"02","key":"ref118","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/rth2.12100","article-title":"Biomarkers, menopausal hormone therapy and risk of venous thrombosis: the Women's Health Initiative","volume":"2","author":"M Cushman","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"02","key":"ref119","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/labmed\/lmw001","article-title":"Widely used types and clinical applications of D-dimer assay","volume":"47","author":"R S Riley","year":"2016","journal-title":"Lab Med"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-7196-1_7","article-title":"D-dimer testing: laboratory aspects and current issues","volume":"1646","author":"J Thachil","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"03","key":"ref121","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrcardio.2013.211","article-title":"Inherited risk factors for venous thromboembolism","volume":"11","author":"I Martinelli","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"06","key":"ref122","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1160\/TH06-12-0745","article-title":"Association between the plasminogen activator inhibitor-1 4G\/5G polymorphism and venous thrombosis. A meta-analysis","volume":"97","author":"A E Tsantes","year":"2007","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref123","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis","volume":"95","author":"N H van Tilburg","year":"2000","journal-title":"Blood"},{"issue":"04","key":"ref124","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MBC.0b013e32835d543a","article-title":"Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone","volume":"24","author":"M Garand","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"42","key":"ref125","doi-asserted-by":"crossref","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","article-title":"A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor","volume":"273","author":"W Wang","year":"1998","journal-title":"J Biol Chem"},{"issue":"14","key":"ref126","doi-asserted-by":"crossref","first-page":"13340","DOI":"10.1074\/jbc.M313211200","article-title":"Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin","volume":"279","author":"M Schneider","year":"2004","journal-title":"J Biol Chem"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(05)80081-9","article-title":"Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study","volume":"342","author":"T Koster","year":"1993","journal-title":"Lancet"},{"issue":"08","key":"ref128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199402243300801","article-title":"Resistance to activated protein C as a basis for venous thrombosis","volume":"330","author":"P J Svensson","year":"1994","journal-title":"N Engl J Med"},{"issue":"01","key":"ref129","first-page":"4","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"S Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study","volume":"354","author":"J Rosing","year":"1999","journal-title":"Lancet"},{"issue":"03","key":"ref131","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C","volume":"90","author":"B Dahlb\u00e4ck","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"ref132","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ajh.23867","article-title":"Activated protein C resistance testing for factor V Leiden","volume":"89","author":"S Kadauke","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"ref133","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"A Dahm","year":"2003","journal-title":"Blood"},{"issue":"07","key":"ref134","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"M C de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613145","article-title":"Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test","volume":"88","author":"J Curvers","year":"2002","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref136","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women","volume":"122","author":"G Tans","year":"2003","journal-title":"Br J Haematol"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"S N Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"issue":"04","key":"ref138","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/13625187.2014.918596","article-title":"Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women","volume":"19","author":"R E Nappi","year":"2014","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"02","key":"ref139","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"J Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"05","key":"ref140","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1538-7836.2010.03773.x","article-title":"Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels","volume":"8","author":"G Lavigne-Lissalde","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref141","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.thromres.2012.03.009","article-title":"Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center","volume":"129","author":"A Marco","year":"2012","journal-title":"Thromb Res"},{"issue":"02","key":"ref142","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2010.10.017","article-title":"Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux","volume":"127","author":"F Szlam","year":"2011","journal-title":"Thromb Res"},{"issue":"04","key":"ref143","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1160\/TH07-09-0581","article-title":"Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma","volume":"99","author":"J Duchemin","year":"2008","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref144","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jth.14745","article-title":"Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance","volume":"18","author":"L Morimont","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref145","first-page":"1","article-title":"PB1224 | Assessment of the APC resistance measured by thrombin generation and clot waveform analysis: a pilot study \u2014 special issue: abstracts of the XXVII Congress of the International Society on Thrombosis and Haemostasis, July 6\u201310, 2019","volume":"3","author":"J Evrard","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S 02","key":"ref146","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.3109\/13625187.2010.513071","article-title":"History of oral contraception","volume":"15","author":"M Dhont","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"02","key":"ref147","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"E Previtali","year":"2011","journal-title":"Blood Transfus"},{"issue":"07","key":"ref148","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/jth.13349","article-title":"Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis","volume":"14","author":"E F van Vlijmen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"S 03","key":"ref149","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0049-3848(11)70009-3","article-title":"Epidemiology of the contraceptive pill and venous thromboembolism","volume":"127","author":"P C Hannaford","year":"2011","journal-title":"Thromb Res"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:41:56Z","timestamp":1696920116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":140,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714140","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]}}}